{"id":"investigational-23-valent-ppv","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain, erythema, or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia or arthralgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified capsular polysaccharides from 23 different serotypes of pneumococcus conjugated or presented to elicit a humoral immune response. This induces B-cell activation and antibody production (primarily IgG) that provides protection against invasive pneumococcal disease and pneumococcal pneumonia caused by the included serotypes. As a polysaccharide vaccine, it primarily activates T-cell-independent B-cell responses.","oneSentence":"A 23-valent pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:50:11.168Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults and children"}]},"trialDetails":[{"nctId":"NCT05477693","phase":"PHASE4","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-10-25","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT04989465","phase":"PHASE4","title":"A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-09-10","conditions":"Pneumococcal Infections","enrollment":600},{"nctId":"NCT02451969","phase":"PHASE3","title":"Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2015-04","conditions":"Pneumococcal Infections","enrollment":1760}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Investigational 23-valent PPV","genericName":"Investigational 23-valent PPV","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"A 23-valent pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}